Stockreport

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]

Imunon, Inc.  (IMNN) 
PDF non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin ® ) and [Read more]